Eight minor cannabinoids showed activity at CB1 and CB2 receptors in cells and produced cannabinoid-like effects in mice
A systematic study of 8 phytocannabinoids found that several minor compounds (THCV, CBG, CBC, and cannabinoid acids) showed partial agonist activity at CB1 and/or CB2 receptors and produced behavioral effects in mice.
Quick Facts
What This Study Found
THC, THCA, THCV, CBD, CBDA, CBDV, CBG, and CBC were tested for receptor binding, cAMP inhibition, beta-arrestin2 recruitment, and in vivo effects. Multiple minor cannabinoids displayed partial agonist activity at CB1 and/or CB2. Several produced cannabinoid-like tetrad effects in mice (catalepsy, hypothermia, antinociception, hypolocomotion) and anxiolytic-like effects.
Key Numbers
8 phytocannabinoids tested. Multiple showed partial CB1R and/or CB2R agonist activity. In vivo tetrad effects and anxiolytic responses observed for several compounds.
How They Did This
In vitro: CHO cells stably expressing human CB1R or CB2R tested for binding affinity, cAMP inhibition, beta-arrestin2 recruitment, and ligand bias. In vivo: C57BL/6 mice tested in the cannabinoid tetrad battery and elevated plus maze for anxiety.
Why This Research Matters
Most cannabis research focuses on THC and CBD, but cannabis contains over 120 cannabinoids. Understanding the pharmacology of minor compounds is essential for explaining whole-plant effects and developing targeted therapeutics.
The Bigger Picture
The finding that many minor cannabinoids have their own receptor activity supports the "entourage effect" concept and suggests that the therapeutic potential of cannabis extends well beyond THC and CBD.
What This Study Doesn't Tell Us
In vitro studies used overexpression cell systems that may not reflect physiological receptor levels. Mouse behavioral tests provide limited insight into human effects. Compounds were tested individually, not in combination as they occur in plant material.
Questions This Raises
- ?How do these minor cannabinoids interact with each other and with THC/CBD in combination?
- ?Could specific minor cannabinoids be developed as standalone therapeutics?
- ?Do the receptor selectivity profiles predict which compounds might be useful for specific conditions?
Trust & Context
- Key Stat:
- Multiple minor cannabinoids showed CB1/CB2 partial agonist activity
- Evidence Grade:
- Comprehensive in vitro characterization with in vivo validation, but preclinical data only. Overexpression systems may amplify receptor activity.
- Study Age:
- 2020 study. One of the most comprehensive pharmacological characterizations of minor phytocannabinoids to date.
- Original Title:
- In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.
- Published In:
- Scientific reports, 10(1), 20405 (2020)
- Authors:
- Zagzoog, Ayat(6), Mohamed, Kawthar A(2), Kim, Hye Ji J, Kim, Eunhyun D, Frank, Connor S, Black, Tallan, Jadhav, Pramodkumar D, Holbrook, Larry A, Laprairie, Robert B
- Database ID:
- RTHC-02932
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What are minor cannabinoids?
Minor cannabinoids are compounds found in cannabis at lower concentrations than THC and CBD. They include THCV, CBG, CBC, and the acidic forms (THCA, CBDA, CBDV). This study found many have their own receptor activity.
Does this support the entourage effect?
The finding that multiple minor cannabinoids independently activate CB1 and/or CB2 receptors supports the idea that whole-plant cannabis effects result from the combined actions of many compounds, not just THC.
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
Cite This Study
https://rethinkthc.com/research/RTHC-02932APA
Zagzoog, Ayat; Mohamed, Kawthar A; Kim, Hye Ji J; Kim, Eunhyun D; Frank, Connor S; Black, Tallan; Jadhav, Pramodkumar D; Holbrook, Larry A; Laprairie, Robert B. (2020). In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.. Scientific reports, 10(1), 20405. https://doi.org/10.1038/s41598-020-77175-y
MLA
Zagzoog, Ayat, et al. "In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.." Scientific reports, 2020. https://doi.org/10.1038/s41598-020-77175-y
RethinkTHC
RethinkTHC Research Database. "In vitro and in vivo pharmacological activity of minor canna..." RTHC-02932. Retrieved from https://rethinkthc.com/research/zagzoog-2020-in-vitro-and-in
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.